

# Regence

Medical Policy Manual

Medicine, Policy No. 142

## ***Orthopedic Applications of Stem Cell Therapy, Including Bone Substitutes Used with Autologous Bone Marrow***

**Effective:** February 1, 2025

**Next Review:** October 2025

**Last Review:** December 2024

### **IMPORTANT REMINDER**

Medical Policies are developed to provide guidance for members and providers regarding coverage in accordance with contract terms. Benefit determinations are based in all cases on the applicable contract language. To the extent there may be any conflict between the Medical Policy and contract language, the contract language takes precedence.

PLEASE NOTE: Contracts exclude from coverage, among other things, services or procedures that are considered investigational or cosmetic. Providers may bill members for services or procedures that are considered investigational or cosmetic. Providers are encouraged to inform members before rendering such services that the members are likely to be financially responsible for the cost of these services.

### **DESCRIPTION**

Mesenchymal stem cells (MSCs) are multipotent cells (also called “stromal multipotent cells”) that possess the ability to differentiate into various tissues including organs, trabecular bone, tendon, articular cartilage, ligaments, muscle, and fat. Potential uses of MSCs for orthopedic applications include treatment of damaged bone, cartilage, ligaments, tendons, and intervertebral discs.

### **MEDICAL POLICY CRITERIA**

**Note:** Use of platelet rich plasma is addressed in Medicine Policy No. 77 (see Cross References section). This policy does not apply to the use of unmanipulated bone marrow aspirate for spinal indications which may be considered medically necessary.

- I. Mesenchymal stem cell therapy, including but not limited to manipulated or unmanipulated bone marrow, fat, and amnion cells, is considered **investigational** for all orthopedic applications, including but not limited to use in repair or regeneration of musculoskeletal tissue.

- II. Allograft bone products containing viable stem cells are considered **investigational** for all orthopedic applications, including but not limited to demineralized bone matrix (DBM) with stem cells.
- III. Synthetic bone graft substitutes that must be combined with autologous bone marrow are considered **investigational** for all orthopedic applications.

*NOTE: A summary of the supporting rationale for the policy criteria is at the end of the policy.*

## CROSS REFERENCES

1. [Autologous Blood-Derived Growth Factors as a Treatment for Wound Healing and Other Conditions](#), Medicine, Policy No. 77
2. [Progenitor Cell Therapy for the Treatment of Damaged Myocardium Due to Ischemia](#), Medicine, Policy No. 100
3. [Stem-cell Therapy for Peripheral Arterial Disease](#), Medicine, Policy No. 141
4. [Autologous Chondrocyte Implantation for Focal Articular Cartilage Lesions](#), Surgery, Policy No. 87

## BACKGROUND

MSCs are associated with the blood vessels within bone marrow, synovium, fat, and muscle where they can be mobilized for endogenous repair, as occurs with healing of bone fractures. Stimulation of endogenous MSCs is the basis of procedures such as bone marrow stimulation (e.g., microfracture) and harvesting/grafting of autologous bone for fusion. Bone-marrow aspirate is considered to be the most accessible source and, thus, the most common place to isolate MSCs for treatment of musculoskeletal disease. However, harvesting MSCs from bone marrow requires an additional procedure that may result in donor-site morbidity. In addition, the number of MSCs in bone marrow is low, and the number and differentiation capacity of bone marrow-derived MSCs decreases with age, limiting their efficiency when isolated from older patients.

Tissues such as muscle, cartilage, tendon, ligaments, and vertebral discs show limited capacity for endogenous repair. Tissue engineering techniques are being developed to improve the efficiency of repair or regeneration of damaged musculoskeletal tissues. Tissue engineering focuses on the integration of biomaterials with MSCs and/or bioactive molecules such as growth factors. In vivo, the fate of stem cells is regulated by signals in the local 3-dimensional microenvironment from the extracellular matrix and neighboring cells. It is believed that the success of tissue engineering with MSCs will also require an appropriate 3-dimensional scaffold or matrix, culture conditions for tissue-specific induction, and implantation techniques that provide appropriate biomechanical forces and mechanical stimulation. Given that each tissue type requires different culture conditions, induction factors (e.g., signaling proteins, cytokines, growth factors), and implantation techniques, each preparation must be individually examined. The ability to induce cell division and differentiation, without adverse effects such as the formation of neoplasms, remains a significant concern.

The U.S. Food and Drug Administration (FDA) stated:

“Cell-based therapies show great promise for repairing, replacing, restoring, or regenerating damaged cells, tissues and organs. Researchers are working to develop cell-based treatments that are both effective and safe. Many cell-based therapies use stem cells (SC) that are removed from the body and put into cultures in the laboratory, where they multiply before being

infused into the patient. SCs are immature cells that replicate themselves and have the ability to give rise to a variety of different types of cells. For cell therapies based on embryonic stem cells, stem cells are first stimulated to mature before they are given to a patient. However, embryonic stem cells can cause tumors, so products based on them should not have undifferentiated embryonic stem cells contaminating the product given to patients. Also, more mature cells may be better suited for replacing specific types of damaged or lost cells, or for repairing damaged tissue.

A major challenge posed by SC therapy is the need to ensure their efficacy and safety. Cells manufactured in large quantities outside their natural environment in the human body can become ineffective or dangerous and produce significant adverse effects, such as tumors, severe immune reactions, or growth of unwanted tissue. In response to this challenge, FDA scientists are developing laboratory techniques that will enable the agency to carefully evaluate and characterize these products in order to reliably predict whether they will be safe and effective.”

## **REGULATORY STATUS**

Concentrated autologous MSCs do not require approval by the U.S. Food and Drug Administration (FDA).

Demineralized bone matrix (DBM), which is processed allograft bone, is considered minimally processed tissue and does not require FDA approval. At least four commercially available DBM products are reported to contain viable stem cells:

- Allostem® (AlloSource) is partially demineralized allograft bone seeded with adipose-derived MSCs
- Allopatch®,
- Osteocell Plus® (NuVasive): an allograft cellular bone matrix containing native MSCs.
- Trinity Evolution Matrix™ (Orthofix): an allograft that is processed and cryopreserved to maintain viable adult MSCs and osteoprogenitor cells.

Whether these products can be considered minimally manipulated tissue is debated. A product would not meet the criteria for FDA regulation part 1271.10 if it is dependent upon the metabolic activity of living cells for its primary function. Otherwise, a product would be considered a biologic product and would need to demonstrate safety and efficacy for the product's intended use with an investigational new drug and Biologics License Application (BLA).

Other products contain DBM and may be mixed with bone marrow aspirate. Some of the products that are currently available are:

- DBX® Putty (Musculoskeletal Transplant Foundation [MTF]) may be mixed with blood or bone marrow.
- Fusion Flex™ (Wright Medical): a dehydrated moldable DBM scaffold that will absorb autologous bone marrow aspirate.
- Ignite® (Wright Medical): an injectable graft with DBM that can be combined with autologous bone marrow aspirate.
- PliaFX® Prime (LifeNet Health) consists of demineralized bone fibers that may be combined with autograft or allograft materials.

Other commercially available products are intended to be mixed with bone marrow aspirate and have received 510(k) clearance, such as:

- CopiOs sponge or paste (Zimmer): synthetic bone graft material consisting of mineralized, lyophilized collagen.
- Collage™ Putty (Orthofix): Composed of type-1 bovine collagen and beta Tri-calcium phosphate.
- Vitoss® (Stryker, developed by Orthovita): composed of beta tricalcium phosphate.
- nanOss® Bioactive (XTant Medical, developed by Pioneer Surgical): nanostructured hydroxyapatite and an open structured engineered collagen carrier.

No products using engineered MSCs have been approved by the FDA for orthopedic applications.

In 2008, the FDA determined that the mesenchymal stem cells sold by Regenerative Sciences for use in the Regenexx™ procedure would be considered drugs or biological products and thus require submission of a New Drug Application (NDA) or Biologics Licensing Application (BLA) to the FDA. In 2014, a federal appellate court upheld FDA's power to regulate adult stem cells as drugs and biologics and ruled that the Regenexx cell product fell within FDA's authority to regulate human cells, tissues, and cellular and tissue-based products (HCT/Ps) (Section 351).<sup>[1]</sup> To date, no NDA or BLA has been approved by the FDA for this product. As of 2015, the expanded stem cell procedure is only offered in the Cayman Islands. Regenexx™ network facilities in the U.S. provide same-day stem cell and blood platelet procedures, which do not require FDA approval.

## EVIDENCE SUMMARY

At this time, the literature consists mainly of articles describing the potential of stem cell therapy for orthopedic applications in humans, along with basic science experiments on sources of mesenchymal stem cells (MSCs), regulation of cell growth and differentiation, and development of scaffolds.<sup>[2]</sup> Although the evidence base has been steadily increasing, authors indicate that the technology is in an early stage of development. In order to assess the safety and efficacy of orthopedic applications of MSCs and allograft bone products, such as demineralized bone matrix, high-quality randomized trials (RCTs) are required that compare health outcomes with versus without the use of these products.

### CARTILAGE DEFECTS

#### Systematic Reviews

Sadeghirad (2024) published a systematic review and meta-analysis of randomized studies to assess the effectiveness of MSC for chronic knee pain due to osteoarthritis (OA).<sup>[3]</sup> The study involved 16 trials and 807 participants. Thirteen studies used autologous MSC cells and three used allografts. MSC sources were bone-marrow derived in six studies and adipose-derived in eight studies. One study used cells from stromal vascular fraction, and one used placenta-derived cells. At 3-6 months follow-up the analysis found low certainty evidence that MSC injection may reduce pain compared to placebo or conservative management, however high heterogeneity was noted (weighted mean difference [WMD] -2.04 cm on a 10 cm VAS, 95% CI: -2.87 to -1.21;  $I^2 = 87.2\%$ ). At six months, moderate certainty evidence found little to no pain relief (WMD -0.74 cm on a 10cm VAS, 95% CI -1.16 to 1.0.33;  $I^2 = 0$ ). Similarly at one-year follow-up from six studies (252 participants) there was low certainty evidence of reduced

pain (WMD -1.77 cm on a 10 cm VAS, 95% CI: -3.23 to -0.32,  $I^2=87\%$ ) and moderate certainty evidence reported less pain relief (WMD -.0.73 cm on a 10 cm VAS, 95% CI: -1.69 to 0.24,  $I^2=49.6\%$ ). There was also no evidence of improvement in physical function and some evidence that MSC therapy may increase risk of any adverse event (risk ratio [RR] 2.67, 95% CI 1.19 to 5.99).

Jin (2022) published a systematic review and meta-analysis of 6 RCTs (N=452) that evaluated intra-articular MSC injection in patients undergoing high tibial osteotomy (HTO).<sup>[4]</sup> Results demonstrated that there were no significant differences in the International Knee Documentation Committee (IKDC) score and KOOS Pain and Symptoms subscales in patients who underwent HTO with or without the MSC injection. However, patients who received MSC injection had significantly greater improvements in Lysholm scores (mean difference, 2.55; 95% CI, 0.70 to 4.40;  $p=.007$ ), and greater proportions of International Cartilage Regeneration and Joint Preservation Society (ICRS) grade 1 ( $p=.03$ ) and grade 2 ( $p=.02$ ) cartilage repair in the medial femoral condyle and grade 2 cartilage repair in the tibial plateau ( $p=.04$ ).

Rinonpoli (2021) summarized the state of art in the application of stem cells for the treatment of meniscal damage both at pre-clinical and clinical level.<sup>[5]</sup> Of the 18 studies, 13 were preclinical studies, and 5 were clinical trials. The most commonly used cells were mesenchymal stem cells (MSC), derived from bone marrow (BMSC), synovial tissue (SMSC), or adipose tissue (ADSC). Follow-ups ranged from 2 to 16 weeks for the pre-clinical studies and from 3 to 24 months for the clinical studies. All studies documented good results in terms of laboratory markers/scores, clinical and radiologic evaluation. The authors concluded that based on the currently available data, it is not possible to establish the best cell source or delivery method for the treatment of meniscal injuries.

Wiggers (2021) conducted a systematic review of RCTs evaluating autologous MSC therapy on patient-reported outcome measures and disease severity.<sup>[6]</sup> Fourteen RCTs were identified in searches conducted through December 2020. Meta-analysis was precluded because most of the original trial data were not available for pooling and due to heterogeneity across studies. A total of 408 patients with knee osteoarthritis received MSC therapy derived from bone marrow, adipose tissue or activated peripheral blood. After 1 year, 19 of 26 (73%) clinical outcome measures improved with MSCs compared with control. In the MSC group, patients improved by 1.8 to 4.4 points on the Visual Analogue Scale (0 to 10) and 18 to 32 points of the Knee Osteoarthritis Outcome Score (0 to 100). Four studies showed better disease severity on imaging after MSC compared with control at 1 year. Although the reviewers found a positive effect of autologous MSC therapy compared with control treatments, the certainty of the evidence was rated low to very low due to high risk of bias in the included studies (e.g., 10 of 14 RCTs were at high risk of bias on all outcomes) and high heterogeneity in the source, method of preparation, and dosage of injected stem cells in included RCTs.

A systematic review and meta-analysis by Maheshwer (2020) identified 25 studies with 439 participants that used MSCs for treatment of OA.<sup>[7]</sup> Although 13 studies were considered level I RCTs by the authors (range of 7 to 40 participants), low quality RCTs would normally be downgraded to level II. Meta-analysis suggested improvement in self-reported function, but only in patients who underwent concomitant surgery, and there was no significant improvement in pain. Few studies reported on cartilage quality. Most of the studies were rated as poor or fair quality. Conclusions are limited due to substantial variability in MSC source, preparation, and concentration in the current literature.

A systematic review by Borakati (2018) included 13 studies comparing patients with osteoarthritis who were treated either with MSCs or with a control treatment that was identical other than the inclusion of MSCs (i.e., studies using chondrogenic cellular therapy as a control were not included).<sup>[8]</sup> Pain assessment results were noted for each of the controlled studies, resulting in a pooled standardized mean difference (SMD) of -1.27 (95% confidence interval [CI] -1.95 to -0.58) in favor of the group treated with MSCs. Reviewers reported a Z-statistic effect size of 3.62, again in favor of the groups treated with MSCs ( $p < 0.001$ ); although they noted the high heterogeneity across controlled studies ( $I^2 = 92\%$ ). Additionally, 34 uncontrolled studies ( $n = 737$  patients) were summarized and evaluated qualitatively: reviewers noted consistent cartilage regrowth and reduction of pain following treatment with MSCs in these studies; however, as pain medication was often given concurrently, interpretation of the latter outcome is limited.

Emadedin (2018) reported a triple-blind placebo-controlled phase 1/2 trial of expanded MSCs in 47 patients with OA of the knee.<sup>[9]</sup> Compared to the placebo group, the MSC group showed statistically significant improvements in WOMAC pain and function subscales but not VAS. The WOMAC stiffness subscale improved to a similar extent in the two groups. Minimum Clinically Important Improvement and Patient Acceptable Symptom State were not significantly different between the two groups. Study limitations included the short duration of follow-up, statistical analysis, and lack of information regarding use of analgesic medications.

Iijima (2018) published a systematic review of MSC treatment for knee osteoarthritis, which included 35 studies.<sup>[10]</sup> Of these, only seven were RCTs. Meta-analysis results indicated that there was improvement in knee pain (SMD -1.45, 95% CI -1.94 to -0.96), cartilage quality (SMD -1.99, 95% CI -3.51 to -0.47), and self-reported function (SMD 1.50, 95% CI 1.09 to 1.92), however the authors stated that the evidence quality was "very low" to "low," and emphasized the need for high-quality RCTs.

Another 2018 systematic review on stem cell therapy for articular cartilage repair noted similar concerns regarding the quality of the evidence.<sup>[11]</sup> The review included 46 studies that evaluated MSCs from a variety of sources, most of which were case reports and case series. The authors noted that among these, "18 studies erroneously referred to adipose tissue-derived stromal vascular fractions as "adipose-derived MSCs," 2 studies referred to peripheral blood-derived progenitor cells as "peripheral blood-derived MSCs," and 1 study referred to bone marrow aspirate concentrate as "bone marrow-derived MSCs."

Cui (2016) published a systematic review on 18 studies looking at the effect of MSC in treating patients with osteoarthritis.<sup>[12]</sup> MSC treatment in patients with KOA showed continual efficacy for 24 months compared with their pretreatment condition. Effectiveness of MSCs was improved at 12 and 24 months post-treatment, compared with at three and six months. There was no dose response association in the MSCs numbers. This review only included four randomized trials while the remaining 14 studies were non-randomized and had methodological limitations.

Xu (2015) published a meta-analysis on the effect of MSCs for articular cartilage degeneration treatment, including 11 controlled trials ( $n = 558$ ). No critical appraisal of the quality of the included studies was reported. MSC treatment significantly improved the American Orthopedic Foot and Ankle Society Scale (SMD 0.91, 95% confidence interval [CI], 0.52 to 1.29) and the Osteo-Arthritis Outcome Score (SMD 2.81, 95% CI 2.02 to 3.60).<sup>[13]</sup> Comprehensive evaluation indexes, such as the American Knee Society Knee Score System (SMD -0.12, 95% CI -1.02 to

0.78), the Hospital for Special Surgery Knee Rating Scale (SMD 0.24, 95% CI -0.56 to 1.05) and the International Knee Documentation Committee (SMD -0.21, 95% CI -0.77 to 0.34), were no different between MSC use and other treatments. The reviewers concluded that there was no obvious advantage regarding the application of stem cells to treat cartilage injury, compared with other treatments.

Filardo (2013) conducted a systematic review of mesenchymal stem cells for the treatment of cartilage lesions.<sup>[14]</sup> They identified 72 preclinical papers and 18 clinical reports. Of the 18 clinical reports, none were randomized, five were comparative, six were case series, and seven were case reports. In two clinical studies the source of MSCs was adipose tissue, in five it was bone marrow concentrate, and in 11 studies the source of MSCs was bone marrow-derived. The authors reached the following conclusion:

“Despite the growing interest in this biological approach for cartilage regeneration, knowledge on this topic is still preliminary, as shown by the prevalence of preclinical studies and the presence of low-quality clinical studies. Many aspects have to be optimized, and randomized controlled trials are needed to support the potential of this biological treatment for cartilage repair and to evaluate advantages and disadvantages with respect to the available treatments.”

The source of MSCs may have an impact on outcomes, but this is not well understood, and the available literature uses multiple different sources of MSC. Because of the uncertainty over whether these products are equivalent, the summary of the key evidence to date is grouped by source of MSC.

## **Randomized Controlled Trials**

### Cartilage Defects: MSCs Expanded from Bone Marrow

Mautner (2023) compared multiple autologous and allogeneic cell-based therapies with gold-standard corticosteroid injection in 475 adults with OA of the knee in a single-blind phase 3 RCT.<sup>[15]</sup> Patients were randomized to one of two autologous cell therapies (bone marrow aspirate concentrate [BMAC] or stromal vascular fraction), allogeneic umbilical cord-derived MSCs, or intra-articular corticosteroid injection; the co-primary endpoints were changes from baseline in VAS and Knee injury and Osteoarthritis Outcome Score pain scores at 12-month follow-up. No significant differences in pain scores were noted in comparisons between corticosteroid injection and any of the cell therapy arms. The authors concluded that the study found no superiority of any of the cell therapies compared to corticosteroids at one year.

Wong (2013) reported on the use of cultured MSCs in 56 patients with osteoarthritis who underwent medial opening-wedge high tibial osteotomy and microfracture of a cartilage lesion.<sup>[16]</sup> Bone marrow was harvested at the time of microfracture and the MSCs were isolated and cultured. After three weeks, the cells were assessed for viability and delivered to the clinic, where patients received an intra-articular injection of MSCs suspended in hyaluronic acid (HA) or, for controls, intra-articular injection of HA alone. The primary outcome was the International Knee Documentation Committee (IKDC) score at six months, one year, and two years. Secondary outcomes were the Tegner and Lysholm scores through two years and the Magnetic Resonance Observation of Cartilage Repair Tissue (MOCART) scoring system by MRI at one year. All patients completed the two-year follow-up. After adjusting for age, baseline scores, and time of evaluation, the group treated with MSCs showed significantly better scores on the IKDC (mean difference 7.65 on 0 to 100 scale,  $p=0.001$ ), Lysholm (mean

difference, 7.61 on 0 to 100 scale,  $p=0.02$ ), and Tegner (mean difference 0.64 on a 0 to 10 scale,  $p=0.02$ ). Blinded analysis of MRI results found higher MOCART scores in the MSC group. The group treated with MSCs had a higher proportion of patients who had complete cartilage coverage of their lesions (32% vs 0%), greater than 50% cartilage cover (36% vs 14%) and complete integration of the regenerated cartilage (61% vs 14%).

A controlled, double-blind clinical trial was conducted with a group of 47 patients with radiographic and symptomatic knee osteoarthritis.<sup>[17]</sup> Three groups were randomized for intra-articular injections: autologous bone marrow-derived culture-expanded MSCs ( $n=16$ ); autologous bone marrow-derived culture-expanded MSCs with platelet-rich plasma (PRP) ( $n=14$ ); and corticosteroid ( $n=17$ ). The results of the study show Knee Injury and Osteoarthritis Outcome Score (KOOS) is significantly improved at one month ( $p=0.003$ ) with MSCs and by one year both MSCs and MSCS + PRP show the highest percentage of improvement.

#### Cartilage Defects: MSCs Concentrated from Bone Marrow

A small RCT published by Vega (2015) that assessed the efficacy of bone marrow derived MSCs as a treatment for knee osteoarthritis, randomizing 30 patients with chronic knee pain unresponsive to conservative treatments and showing radiological evidence of osteoarthritis.<sup>[18]</sup> Fifteen patients were treated with allogeneic bone marrow MSCs by intra-articular injection, while 15 controls received intra-articular hyaluronic acid (HA). Clinical outcomes were followed for one year and included evaluations of pain, disability, and quality of life. Articular cartilage quality was assessed by quantitative magnetic resonance imaging T2 mapping. The MSC-treated patients displayed significant improvement in algofunctional indices versus the active controls. Quantification of cartilage quality by T2 relaxation measurements showed a significant decrease in poor cartilage areas, with cartilage quality improvements in MSC-treated patients.

#### Cartilage Defects: Adipose-Derived MSCs

Kim (2023) reported a double-blind phase 3 RCT comparing a single intra-articular injection of autologous adipose tissue-derived MSCs with placebo in patients with knee OA ( $N=261$ ).<sup>[19]</sup> Patients meeting American College of Rheumatology criteria for Kellgren-Lawrence grade 3 knee OA who had 100 mm VAS pain scores  $\geq 50$  and WOMAC functional impairment scores  $\geq 40$  despite  $>3$  months of non-operative treatment were eligible for enrollment. All patients underwent abdominal subcutaneous lipoaspiration three weeks prior to assigned study injection (1:1 randomization to  $1 \times 10^8$  autologous adipose tissue-derived MSCs [ $n=131$ ] or a mixture of saline with autologous serum [ $n=130$ ]). The co-primary endpoints were change in 100 mm VAS pain score and WOMAC function score from baseline to 6 months. In the primary analysis, patients assigned to adipose tissue-derived MSCs experienced significantly greater improvements than those assigned to placebo in both VAS pain score ( $25.2 \pm 24.6$  vs  $15.5 \pm 23.7$ ;  $p=.004$ ) and WOMAC function score ( $21.7 \pm 18.6$  vs  $14.3 \pm 19.2$ ;  $p=.002$ ) from baseline to 6 months. Six-month changes in patient-reported outcomes (KOOS, 36-Item Short Form Health Survey Score, and International Knee Documentation Committee subjective knee score) also reflected significant improvements in patients who received adipose tissue-derived MSCs compared with those who received placebo. Study limitations include that while patients were required to have received prior non-operative therapy for at least 3 months, specific prior treatments were not reported; it is unclear whether the use of a placebo comparator was more appropriate than an active comparator in this setting.



The literature on adipose-derived MSCs for articular cartilage repair is very limited, coming from two research groups in Korea. One of the groups appears to have been providing this treatment as an option for patients for a number of years and recently published a RCT that evaluated cartilage healing after high tibial osteotomy (HTO) in 52 patients with osteoarthritis of the medial compartment.<sup>[20]</sup> Patients were randomly assigned to HTO with application of platelet-rich plasma (PRP) or HTO with application of PRP plus MSCs. MSCs from adipose tissue were obtained through liposuction from the buttocks. The tissue was centrifuged and the stromal vascular fraction mixed with PRP for injection. A total of 44 patients completed second look arthroscopy and one- and two-year clinical follow-up. There were statistically significant differences for PRP only versus PRP+MSC on the Knee Injury and Osteoarthritis Outcome Score (KOOS) subscales for pain ( $74 \pm 5.7$  vs.  $81.2 \pm 6.9$ ,  $p < 0.001$ ) and symptoms ( $75.4 \pm 8.5$  vs.  $82.8 \pm 7.2$ ,  $p = 0.006$ ). There were also statistically significant differences on the final pain score for the PRP only versus PRP+MSC groups ( $16.2 \pm 4.6$  vs.  $10.2 \pm 5.7$ ,  $p < 0.001$ ), but the Lysholm score, which is more scientifically proven, was not significantly different between the PRP only and PRP+MSC groups ( $80.6 \pm 13.5$  vs.  $84.7 \pm 16.2$ , all respectively,  $p = 0.36$ ). Articular cartilage healing was rated as improved with MSCs following video review of second-look arthroscopy; blinding of this measure is unclear. There are a number of limitations of this study, including the small sample size, short duration of follow-up, and significant improvements on only some of the outcomes. All of the significant differences in outcomes were modest in magnitude, and as a result, there is uncertainty regarding the clinical significance of the findings.

This group also published a trial comparing treatment with adipose-derived MSCs, fibrin glue, and microfracture to microfracture alone.<sup>[21]</sup> A total of 80 patients with a single International Cartilage Repair Society grade III/IV symptomatic cartilage defect on the femoral condyle were randomized to receive one of the treatments. The mean follow-up time was 27.4 months. At follow-up, the MSC + fibrin glue + microfracture group had significantly greater improvements in the Knee Injury and Osteoarthritis Outcome Score pain and symptom subscores than the microfracture alone group ( $p = 0.034$  and  $0.005$ , respectively). There were no significant differences between groups for the activities of daily living, sports and recreation, or quality of life subscores. Second-look arthroscopies were performed in 57 of the 80 patients, with no significant differences between groups. The lack of blinding in this study limits the conclusions that can be drawn from its results.

More recently, Zaffagnini (2022) reported on results of an RCT that evaluated a single intra-articular injection of microfragmented adipose tissue or PRP in patients ( $N = 118$ ) with knee OA.<sup>[22]</sup> The primary outcomes were the IKDC subjective score and the KOOS pain subscore at 6 months. Overall, both treatments provided significant improvements from baseline in clinical outcomes, with no significant differences found between treatment groups. The IKDC scores significantly improved from baseline to 6 months, from  $41.1 \pm 16.3$  to  $57.3 \pm 18.8$  with microfragmented adipose tissue, and from  $44.8 \pm 17.3$  to  $58.4 \pm 18.1$  with PRP. The improvement in the KOOS pain subscore from baseline to 6 months was  $58.4 \pm 15.9$  to  $75.8 \pm 17.4$  with microfragmented adipose tissue and  $63.5 \pm 17.8$  to  $75.5 \pm 16.1$  with PRP. As a secondary outcome, more patients in the microfragmented adipose tissue group with moderate/severe knee OA reached the minimal clinically important difference for the IKDC score at 6 months compared with the PRP group (75.0% vs 34.6%, respectively;  $p = .005$ ).

A multisite prospective double-blinded randomized placebo-controlled clinical trial was conducted in adult patients with symptomatic knee osteoarthritis.<sup>[23]</sup> The trial included 39 eligible patients injected with high-dose, low-dose, or placebo stromal vascular fraction medium obtained from liposuction for intra-articular administration of progenitor cells and

mesenchymal stem cells derived from adipose tissue. After six months, change in WOMAC score was 83.9%, 51.5%, and 25.0%, respectively, and at one year was 89.5%, 68.2%, and 0%, respectively. Significant changes when compared with placebo revealed a dose dependent improvement in osteoarthritis symptoms and pain at six months (high dose,  $p=0.04$ ; low dose,  $p=0.02$ ) and at one year (high dose,  $p=0.006$ ; low dose,  $p=0.009$ ).

#### Cartilage Defects: MSCs from Peripheral Blood

A 2013 report described a small randomized controlled trial with autologous peripheral blood MSCs for focal articular cartilage lesions.<sup>[24]</sup> Fifty patients with grade 3 and 4 lesions of the knee joint underwent arthroscopic subchondral drilling followed by five weekly injections of HA. Half of the patients were randomly allocated to receive injections of peripheral blood stem cells or no further treatment. There were baseline differences in age between the groups, with a mean age of 38 for the treatment group compared to 42 for the control group. The peripheral blood stem cells were harvested after stimulation with recombinant human granulocyte colony-stimulating factor, divided in vials, and cryopreserved. At six months after surgery, HA and MSC were re-administered over three weekly injections. At 18 months after surgery, second look arthroscopy on 16 patients in each group showed significantly ( $p=.022$ ) higher histological scores (by about 10%) for the MSC group (1,066 vs. 957 by independent observers) while blinded evaluation of MRI showed a statistically significant ( $p=0.013$ ) higher morphologic score (9.9 vs. 8.5). There was no difference in International Knee Documentation Committee (IKDC) scores between the two groups at 24 months after surgery. It is uncertain how differences in patient age at baseline may have affected the response to subchondral drilling.

#### Cartilage Defects: MSCs from Synovial Tissue

Akgun (2015) reported a small ( $n=14$ ) investigator-blinded RCT that compared matrix-induced autologous MSCs from synovial tissue versus matrix-induced autologous chondrocyte implantation (MACI).<sup>[25]</sup> Both chondrocytes from cartilage and MSCs from synovia were harvested in an arthroscopic procedure, expanded in culture, and then cultured on a collagen membrane for two days. Implantation was performed with the cells facing the subchondral bone. Follow up evaluations were made through 24 months post-procedure. Outcomes on the KOOS subscales and the VAS pain score were statistically better in the MSC group than the MACI group ( $p<0.05$ ) at the six-month follow up, although it is not clear if the difference observed would be considered clinically significant. Studies with larger samples sizes and follow-up supported by histological analyses are necessary to determine long-term outcomes of this treatment.

#### Cartilage Defects: MSCs from Umbilical Cord Blood

Lim (2021) reported on a RCT of 114 patients with large, full-thickness cartilage defects (International Cartilage Repair Society grade 4) treated with either a composite of umbilical cord-derived MSCs plus 4% hyaluronate (MSC-HA) or microfracture.<sup>[26]</sup> The study consisted of a 48-week phase 3 clinical trial and a 5-year follow-up study (64%). Of 114 patients randomized, 89 completed the phase 3 trial (78.1%) and 73 were enrolled in the follow-up study (64.0%). The primary outcome, proportion of participants with cartilage restoration equivalent to at least 1 grade improvement on the ICRS Macroscopic Cartilage Repair Assessment at 48-week arthroscopic evaluation, was 97.7% (42/43) in the MSC-HA group and 71.7% (33/46) in the microfracture group (odds ratio, 16.55; 95% CI, 2.06 to 133.03;  $P = .001$ ). Both groups had significantly improved patient-reported pain scores (VAS pain, WOMAC, and IKDC scores) at 48 weeks versus baseline, but there was no significant difference between the

2 groups at this timepoint. From 36 to 60 months after intervention, the significant improvements from baseline were maintained in the MSC-HA group, whereas the improvements in VAS pain and WOMAC deteriorated in the microfracture group. This study had several limitations. There was no intervention group that received MSC alone, the comparator (microfracture) is not considered the standard of care for large, full-thickness cartilage defects, surgeons and participants were not blinded to treatment outcome, and there was high loss to follow-up. These limitations, along with a lack of improvement in patient-reported outcomes in the intervention group at 48 weeks, preclude drawing conclusions about the effectiveness of umbilical cord blood-derived MSCs in this population; higher quality evidence from RCTs is needed.

### **Section Summary**

The evidence base on MSCs for cartilage repair is increasing, although nearly all studies to date have reported a variety of methods of MSC preparation. Some randomized studies have reported improvements in histologic, morphologic and functional outcomes, but others have found MSCs are not superior to standard treatment. Meta-analyses have found reduction of pain in groups treated with MSCs, although high heterogeneity is noted. Long-term efficacy has not been established. Studies did not consistently distinguish between improvements due to MSCs and those due to pain medication. The method of preparation used in one positive study was to obtain MSCs from bone marrow at the time of microfracture, culture (expand) over a period of three weeks, and then inject into the knee in a carrier of HA. Another randomized trial, using MSCs from peripheral blood, found improvements in histologic and morphologic outcomes, but not functional outcomes, following stimulation with recombinant human granulocyte colony-stimulating factor. A third small RCT found that MSCs from synovial tissue and cultured in collagen resulted in outcomes at least as good as those following MACI.

### **FUSION AND NON-UNION**

There is limited evidence on the use of allografts with stem cells for fusion of the extremities or spine or for the treatment of non-union. No RCTs for this indication were identified.

Eastlack (2014) reported outcomes from a series of 182 patients who were treated with anterior cervical discectomy and fusion using Osteocel Plus in a PEEK cage and anterior plating.<sup>[27]</sup> At 24 months, 74% of patients (180/249 levels treated) were available for follow-up. These patients had significant improvements in clinical outcomes; 87% of levels achieved solid bridging and 92% of levels had range of motion less than 3°. With 26% loss to follow-up at 24 months and lack of a standard of care control group, interpretation of these results is limited.

One retrospective series from 2009 was identified on the use of Trinity MSC bone allograft for revision surgery of the foot and ankle.<sup>[28]</sup> Twenty-three patients were included who had undergone revision foot and/or ankle surgery for residual malunion, non-union, or significant segmental bone loss. Patients were followed to the point of radiographic and clinical union, which occurred at a median of 72.5 days for 21 of the 23 patients (91.3%). However, these outcomes do not permit conclusions because of a lack of a control group for comparison with patients who received stem-cell therapy.

### **Section Summary**

Current evidence is insufficient to determine whether the use of stem cell results in superior outcomes such as higher fusion rates, or lower rates of reoperations and adverse events.

## **MENISCECTOMY**

Vangsness (2014) reported an industry-sponsored phase 1/2 randomized, double-blind, multicenter study of cultured allogeneic MSCs (Chondrogen™, Osiris Therapeutics) injected into the knee after partial meniscectomy.<sup>[29]</sup> The 55 patients were randomized to intra-articular injection of either 50´10<sup>6</sup> allogeneic MSCs, 150´10<sup>6</sup> allogeneic MSCs in HA, or HA vehicle control at 7 to 10 days after meniscectomy. The cultured MSCs were derived from bone-marrow aspirates from unrelated donors. At two-year follow-up, three patients in the low-dose MSC group had significantly increased meniscal volume measured by MRI (with an a priori determined threshold of at least 15%) compared to none in the control group and none in the high-dose MSC group. There was no significant difference between the groups in the Lysholm Knee Scale. On subgroup analysis, patients with osteoarthritis who received MSCs had a significantly greater reduction in pain at two years compared with patients who received HA alone. This appears to be a post hoc analysis and should be considered preliminary. No serious adverse events were thought to be related to the investigational treatment.

### **Section Summary**

Current evidence for the use of stem cells as an adjunct to meniscectomy is limited to a single preliminary RCT. The outcomes of this study must be validated in large, long-term, randomized controlled trials.

## **OSTEONECROSIS**

Several randomized comparative trials have been identified that evaluated the use of MSCs for osteonecrosis of the femoral head.

### **Osteonecrosis: MSCs Expanded from Bone Marrow**

Zhao (2012) reported a randomized trial that included 100 patients (104 hips) with early stage femoral head osteonecrosis treated with core decompression and expanded bone marrow MSCs versus core decompression (CD) alone.<sup>[30]</sup> At 60 months after surgery, two of the 53 hips (3.7%) treated with MSCs continued to have progressive disease and underwent vascularized bone grafting, compared with 10 of 44 hips (23%) in the decompression group who had disease progression and underwent either vascularized bone grafting (n=5) or total hip replacement (n=5). In addition, treatment with MSC improved Harris Hip scores compared to CD and decreased the volume of the necrotic lesion of the hips preoperatively classified at stage IC, IIB, and IIC (p<0.05, respectively; stage IIA, P=0.06, respectively).

### **Osteonecrosis: MSCs Concentrated from Bone Marrow**

A 2017 randomized, double-blind trial was conducted using autologous bone marrow concentrate in 38 patients with stage three osteonecrosis.<sup>[31]</sup> A control group of core decompression plus saline injection was compared to patients receiving core decompression plus MSC implantation. The primary outcome was needing total hip replacement and secondary outcomes were clinical symptoms such as pain and functional ability. There was no difference between groups on any outcomes including total hip replacement requirements, clinical tests, or radiologic evidence.

Another small trial randomized 40 patients (51 hips) with early stage femoral head osteonecrosis to core decompression plus concentrated bone marrow MSCs or core decompression alone.<sup>[32]</sup> Blinding of assessments in this small trial was not described. Harris

Hip Score (HHS) was significantly improved in the MSC group (scores of 83.65 and 82.42;  $p < 0.05$ ) compared with core decompression (scores of 76.68 and 77.39). Kaplan-Meier analysis showed improved hip survival in the MSC group (mean of 51.9 weeks) compared with the core decompression group (mean of 46.7 weeks). There were no significant differences between the groups in the radiographic assessment or MRI results. The conflicting report of improvement via HHS compared to no observable improvement via MRI, may point to the need for study blinding to control for confounding bias toward treatment.

### **Section Summary**

Two small studies reported improvement in the Harris Hip Score in patients with osteonecrosis of the femoral head treated with core decompression and MSCs, although it was not reported if the patients or investigators were blinded to the treatment group. Hip survival was significantly improved following treatment with either expanded or concentrated MSCs. The effect appears to be larger with expanded MSCs compared with concentrated MSCs. However, a double-blind RCT found no difference between MSC treatment or saline injection, when combined with core decompression. Additional studies with a larger number of patients are needed to permit greater certainty regarding the effect of this treatment on health outcomes.

### **BONE FRACTURES**

A systematic review by Yi (2022) explores the application potential of MSCs for healing bone fractures.<sup>[33]</sup> Of the 31 articles, 26 were preclinical studies ( $n = 913$ ), and 5 were clinical trials ( $n = 335$ ). Preclinically, MSCs therapy significantly augmented the progress of bone regeneration [(bone volume over tissue volume (MD7.35,  $p < 0.01$ )], despite some non-significant effects (on the callus index, bone strength, work to failure, and stiffness). Clinically, the MSC group had a significantly reduced incidence of poor recovery (odds ratio (OR) 0.30,  $p < 0.01$ ); however, a significant decrease in healing time was not observed in the MSC group (MD 2.47,  $p = 0.26$ ). The authors suggest that the patients have benefited from MSC administration but larger RCTs are needed to confirm these findings.

### **Section Summary**

Current evidence for the use of stem cells for healing bone fractures is limited to a single systematic review. Larger RCTs are required to confirm the clinical and preclinical findings.

## **PRACTICE GUIDELINE SUMMARY**

### **American College of Rheumatology and Arthritis Foundation**

In 2019, guidelines from the American College of Rheumatology and Arthritis Foundation on osteoarthritis (OA) of the hand, hip, and knee gave a strong recommendation against stem cell injections in patients with knee and/or hip OA, noting the heterogeneity in preparations and lack of standardization of techniques.<sup>[34]</sup> No recommendation was made for hand OA, since efficacy of stem cells has not been evaluated.

### **American Academy of Orthopaedic Surgeons**

A 2020 guideline from American Association of Orthopaedic Surgeons on the management of glenohumeral joint OA, endorsed by several other societies, states that injectable biologics such as stem cells cannot be recommended in the treatment glenohumeral joint OA.<sup>[35]</sup> There was consensus from the panel that better standardization and high-quality evidence from

clinical trials is needed to provide definitive evidence on the efficacy of biologics in glenohumeral OA. The strength of evidence was rated as no reliable scientific evidence to determine benefits and harms. The 2013 guideline on treatment of osteoarthritis of the knee does not address stem cell injections.

### American Association of Neurological Surgeons

In 2014, the American Association of Neurological Surgeons guidelines on fusion procedures for degenerative disease of the lumbar spine relevant to this evidence review have indicated that “The use of demineralized bone matrix (DBM) as a bone graft extender is an option for 1- and 2-level instrumented posterolateral fusions. Demineralized Bone Matrix: Grade C (poor level of evidence).”<sup>[36]</sup>

## SUMMARY

There is not enough research to know if or how well mesenchymal stem cells (MSCs), allograft bone products containing stem cells, or synthetic bone graft substitutes that must be combined with autologous bone marrow work to treat people with orthopedic conditions. No clinical guidelines based on research recommend MSC treatment, allograft bone products containing stem cells, or synthetic bone graft substitutes that must be combined with autologous bone marrow for people with orthopedic conditions. Therefore, use of stem cells for orthopedic applications is considered investigational.

## REFERENCES

1. Chirba MA, Sweetapple B, Hannon CP, et al. FDA regulation of adult stem cell therapies as used in sports medicine. *The journal of knee surgery*. 2015;28(1):55-62. PMID: 25603042
2. Deans TL, Elisseeff JH. Stem cells in musculoskeletal engineered tissue. *Curr Opin Biotechnol*. 2009;20(5):537-44. PMID: 19879127
3. Sadeghirad B, Rehman Y, Khosravirad A, et al. Mesenchymal stem cells for chronic knee pain secondary to osteoarthritis: A systematic review and meta-analysis of randomized trials. *Osteoarthritis Cartilage*. 2024;32(10):1207-19. PMID: 38777213
4. Jin L, Yang G, Men X, et al. Intra-articular Injection of Mesenchymal Stem Cells After High Tibial Osteotomy: A Systematic Review and Meta-analysis. *Orthop J Sports Med*. 2022;10(11):23259671221133784. PMID: 36452339
5. Rinonapoli G, Gregori P, Di Matteo B, et al. Stem cells application in meniscal tears: a systematic review of pre-clinical and clinical evidence. *Eur Rev Med Pharmacol Sci*. 2021;25(24):7754-64. PMID: 34982437
6. Wiggers TG, Winters M, Van den Boom NA, et al. Autologous stem cell therapy in knee osteoarthritis: a systematic review of randomised controlled trials. *Br J Sports Med*. 2021;55(20):1161-69. PMID: 34039582
7. Maheshwer B, Polce EM, Paul K, et al. Regenerative Potential of Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis and Chondral Defects: A Systematic Review and Meta-analysis. *Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association*. 2021;37(1):362-78. PMID: 32497658

8. Borakati A, Mafi R, Mafi P, et al. A Systematic Review And Meta-Analysis of Clinical Trials of Mesenchymal Stem Cell Therapy for Cartilage Repair. *Current stem cell research & therapy*. 2018;13(3):215-25. PMID: 28914207
9. Emadedin M, Labibzadeh N, Liastani MG, et al. Intra-articular implantation of autologous bone marrow-derived mesenchymal stromal cells to treat knee osteoarthritis: a randomized, triple-blind, placebo-controlled phase 1/2 clinical trial. *Cytotherapy*. 2018;20(10):1238-46. PMID: 30318332
10. Iijima H, Isho T, Kuroki H, et al. Effectiveness of mesenchymal stem cells for treating patients with knee osteoarthritis: a meta-analysis toward the establishment of effective regenerative rehabilitation. *NPJ Regenerative medicine*. 2018;3:15. PMID: 30245848
11. Park YB, Ha CW, Rhim JH, et al. Stem Cell Therapy for Articular Cartilage Repair: Review of the Entity of Cell Populations Used and the Result of the Clinical Application of Each Entity. *The American journal of sports medicine*. 2018;46(10):2540-52. PMID: 29023156
12. Cui GH, Wang YY, Li CJ, et al. Efficacy of mesenchymal stem cells in treating patients with osteoarthritis of the knee: A meta-analysis. *Experimental and therapeutic medicine*. 2016;12(5):3390-400. PMID: 27882169
13. Xu S, Liu H, Xie Y, et al. Effect of mesenchymal stromal cells for articular cartilage degeneration treatment: a meta-analysis. *Cytotherapy*. 2015;17(10):1342-52. PMID: 26122717
14. Filardo G, Madry H, Jelic M, et al. Mesenchymal stem cells for the treatment of cartilage lesions: from preclinical findings to clinical application in orthopaedics. *Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA*. 2013;21(8):1717-29. PMID: 23306713
15. Mautner K, Gottschalk M, Boden SD, et al. Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial. *Nat Med*. 2023;29(12):3120-26. PMID: 37919438
16. Wong KL, Lee KB, Tai BC, et al. Injectable cultured bone marrow-derived mesenchymal stem cells in varus knees with cartilage defects undergoing high tibial osteotomy: a prospective, randomized controlled clinical trial with 2 years' follow-up. *Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association*. 2013;29(12):2020-8. PMID: 24286801
17. Bastos R, Mathias M, Andrade R, et al. Intra-articular injection of culture-expanded mesenchymal stem cells with or without addition of platelet-rich plasma is effective in decreasing pain and symptoms in knee osteoarthritis: a controlled, double-blind clinical trial. *Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA*. 2020;28(6):1989-99. PMID: 31587091
18. Vega A, Martin-Ferrero MA, Del Canto F, et al. Treatment of Knee Osteoarthritis With Allogeneic Bone Marrow Mesenchymal Stem Cells: A Randomized Controlled Trial. *Transplantation*. 2015;99(8):1681-90. PMID: 25822648
19. Kim KI, Lee MC, Lee JH, et al. Clinical Efficacy and Safety of the Intra-articular Injection of Autologous Adipose-Derived Mesenchymal Stem Cells for Knee Osteoarthritis: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial. *The American journal of sports medicine*. 2023;51(9):2243-53. PMID: 37345256
20. Koh YG, Kwon OR, Kim YS, et al. Comparative outcomes of open-wedge high tibial osteotomy with platelet-rich plasma alone or in combination with mesenchymal stem cell treatment: a prospective study. *Arthroscopy : the journal of arthroscopic & related*

- surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association. 2014;30(11):1453-60. PMID: 25108907
21. Koh YG, Kwon OR, Kim YS, et al. Adipose-Derived Mesenchymal Stem Cells With Microfracture Versus Microfracture Alone: 2-Year Follow-up of a Prospective Randomized Trial. *Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association*. 2016;32(1):97-109. PMID: 26585585
  22. Zaffagnini S, Andriolo L, Boffa A, et al. Microfragmented Adipose Tissue Versus Platelet-Rich Plasma for the Treatment of Knee Osteoarthritis: A Prospective Randomized Controlled Trial at 2-Year Follow-up. *The American journal of sports medicine*. 2022;50(11):2881-92. PMID: 35984721
  23. Garza JR, Campbell RE, Tjoumakaris FP, et al. Clinical Efficacy of Intra-articular Mesenchymal Stromal Cells for the Treatment of Knee Osteoarthritis: A Double-Blinded Prospective Randomized Controlled Clinical Trial. *The American journal of sports medicine*. 2020;48(3):588-98. PMID: 32109160
  24. Saw KY, Anz A, Siew-Yoke Jee C, et al. Articular cartilage regeneration with autologous peripheral blood stem cells versus hyaluronic acid: a randomized controlled trial. *Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association*. 2013;29(4):684-94. PMID: 23380230
  25. Akgun I, Unlu MC, Erdal OA, et al. Matrix-induced autologous mesenchymal stem cell implantation versus matrix-induced autologous chondrocyte implantation in the treatment of chondral defects of the knee: a 2-year randomized study. *Archives of orthopaedic and trauma surgery*. 2015;135(2):251-63. PMID: 25548122
  26. Lim HC, Park YB, Ha CW, et al. Allogeneic Umbilical Cord Blood-Derived Mesenchymal Stem Cell Implantation Versus Microfracture for Large, Full-Thickness Cartilage Defects in Older Patients: A Multicenter Randomized Clinical Trial and Extended 5-Year Clinical Follow-up. *Orthop J Sports Med*. 2021;9(1):2325967120973052. PMID: 33490296
  27. Eastlack RK, Garfin SR, Brown CR, et al. Osteocel Plus cellular allograft in anterior cervical discectomy and fusion: evaluation of clinical and radiographic outcomes from a prospective multicenter study. *Spine*. 2014;39(22):E1331-7. PMID: 25188591
  28. Rush SM, Hamilton GA, Ackerson LM. Mesenchymal stem cell allograft in revision foot and ankle surgery: a clinical and radiographic analysis. *The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons*. 2009;48(2):163-9. PMID: 19232968
  29. Vangsness CT, Jr., Farr J, 2nd, Boyd J, et al. Adult human mesenchymal stem cells delivered via intra-articular injection to the knee following partial medial meniscectomy: a randomized, double-blind, controlled study. *The Journal of bone and joint surgery American volume*. 2014;96(2):90-8. PMID: 24430407
  30. Zhao D, Cui D, Wang B, et al. Treatment of early stage osteonecrosis of the femoral head with autologous implantation of bone marrow-derived and cultured mesenchymal stem cells. *Bone*. 2012;50(1):325-30. PMID: 22094904
  31. Hauzeur JP, De Maertelaer V, Baudoux E, et al. Inefficacy of autologous bone marrow concentrate in stage three osteonecrosis: a randomized controlled double-blind trial. *International orthopaedics*. 2017. PMID: 28988340
  32. Sen RK, Tripathy SK, Aggarwal S, et al. Early results of core decompression and autologous bone marrow mononuclear cells instillation in femoral head osteonecrosis: a randomized control study. *The Journal of arthroplasty*. 2012;27(5):679-86. PMID: 22000577



33. Yi H, Wang Y, Liang Q, et al. Preclinical and Clinical Amelioration of Bone Fractures with Mesenchymal Stromal Cells: a Systematic Review and Meta-Analysis. *Cell Transplant*. 2022;31:9636897211051743. PMID: 35916286
34. Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. *Arthritis Care Res (Hoboken)*. 2020;72(2):149-62. PMID: 31908149
35. American Academy of Orthopaedic Surgeons. Management of Glenohumeral Joint Osteoarthritis Evidence-Based Clinical Practice Guideline. [cited 12/03/2024]. 'Available from:' <https://www.aaos.org/globalassets/quality-and-practice-resources/glenohumeral/gjo-cpg.pdf>.
36. Kaiser MG, Groff MW, Watters WC, 3rd, et al. Guideline update for the performance of fusion procedures for degenerative disease of the lumbar spine. Part 16: bone graft extenders and substitutes as an adjunct for lumbar fusion. *J Neurosurg Spine*. 2014;21(1):106-32. PMID: 24980593

## CODES

**NOTE:** There are no specific codes for orthopedic applications of stem cell therapy. The appropriate CPT code for reporting this procedure is 20999, or the code for an unlisted procedure of the body area on which the procedure is performed.

Codes	Number	Description
CPT	0565T	Autologous cellular implant derived from adipose tissue for the treatment of osteoarthritis of the knees; tissue harvesting and cellular implant creation
	0566T	Injection of cellular implant into knee joint using ultrasound guidance, unilateral
	0717T	Autologous adipose-derived regenerative cell (ADRC) therapy for partial thickness rotator cuff tear; adipose tissue harvesting, isolation and preparation of harvested cells, including incubation with cell dissociation enzymes, filtration, washing and concentration of ADRCs
	0718T	Autologous adipose-derived regenerative cell (ADRC) therapy for partial thickness rotator cuff tear; injection into supraspinatus tendon including ultrasound guidance, unilateral
	0737T	Xenograft implantation into the articular surface
	20939	Bone marrow aspiration for bone grafting, spine surgery only, through separate skin or fascial incision (List separately in addition to code for primary procedure)
	20999	Unlisted procedure, musculoskeletal system, general
	21899	Unlisted procedure, neck or thorax
	22899	Unlisted procedure, spine
	23929	Unlisted procedure, shoulder
	24999	Unlisted procedure, humerus or elbow
	25999	Unlisted procedure, forearm or wrist
	26989	Unlisted procedure, hands or fingers
	27299	Unlisted procedure, pelvis or hip joint
	27599	Unlisted procedure, femur or knee
	27899	Unlisted procedure, leg or ankle
	28899	Unlisted procedure, foot or toes
	29999	Unlisted procedure, arthroscopy
	38206	Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; autologous
	38230	Bone marrow harvesting for transplantation; allogeneic
	38232	Bone marrow harvesting for transplantation; autologous

---

<b>Codes</b>	<b>Number</b>	<b>Description</b>
	38241	Bone Marrow or blood-derived peripheral stem cell transplantation; autologous
HCPCS	None	

---

*Date of Origin: September 2011*